In closing arguments made December 1, 2017, counsel for plaintiff urged a jury to find that inadequate Xarelto warnings left the plaintiff with serious internal bleeding. Plaintiffs have argued that Janssen Pharmaceuticals and Bayer Healthcare Pharmaceuticals intentionally understated the risk of serious internal bleeding associated with Xarelto use. The jury is scheduled to begin deliberations on Monday, December 4.
Plaintiff Lynn Hartman is represented by a team of lawyers, including Philadelphia attorney Laura Feldman of Feldman & Pinto. For additional information about the Xarelto drug injury trial (Lynn Hartman v. Janssen Pharmaceuticals, Inc., et al), see this Law360 article.